Demographic Characteristics and Treatment Patterns Among Patients Receiving Palbociclib for HR+/HER2− Advanced Breast Cancer: A Nationwide Real-World Experience

BACKGROUND: This nationwide retrospective study reports data on the real-world use of the selective cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitor palbociclib in a large population of advanced breast cancer (ABC) patients during a 2-year period in Hungary. METHODS: All patients with ABC who rece...

Descripción completa

Detalles Bibliográficos
Autores principales: Boér, Katalin, Rubovszky, Gábor, Rokszin, György, Abonyi-Tóth, Zsolt, Földesi, Csenge, Dank, Magdolna
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2021
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8257075/
https://www.ncbi.nlm.nih.gov/pubmed/34234466
http://dx.doi.org/10.2147/OTT.S309862

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8257075/
https://www.ncbi.nlm.nih.gov/pubmed/34234466
http://dx.doi.org/10.2147/OTT.S309862

Ejemplares similares